Asia Pacific Point of Care Diagnostics Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Product (Glucose Monitoring Products, Infectious Disease Testing Products, Cardiometabolic Testing Products, Pregnancy and Fertility Testing Products, Coagulation Testing Products, Tumor/Cancer Marker Testing Products, Cholesterol Testing Products, Urinalysis Testing Products, Hematology Testing Products, and Other POC Products), Prescription Mode (Prescription-Based Testing and OTC Testing), and End User (Professional Diagnostic Centers, Home Care, Research Laboratories, and Others)


No. of Pages: 194    |    Report Code: TIPRE00023726    |    Category: Life Sciences

Asia Pacific Point of Care Diagnostics Market
Buy Now

Market Introduction

APAC is the fastest-growing market for POC diagnostics, and China, India, Japan, South Korea, Australia, and rest of APAC are the major contributors to the market in this region. China is the largest market of APAC region. The government of China has adopted various comprehensive strategies, including activities such as blood donation screening, promotion of safe injection practices, immunization, and surveillance, to prevent HBV transmission. The China Centers for Disease Control and Prevention also believes that the application of proper infection control practice can lead to success in the prevention of HAIs. However, at the level of average Chinese hospitals, there is no vivid understanding regarding the surveillance of infection and programs to detect, manage, and prevent these HAIs. Many companies have emerged in the country with innovative products and other activities to propel market growth. For instance, in December 2018, Abcam plc. and QIAGEN (Suzhou) Translational Medicine Co., Ltd. signed a Memorandum of Understanding (MoU) agreement. The agreement aims to develop a pipeline of Companion Diagnostics (CDx) as well as in vitro diagnostic reagents and kits to meet the needs of the Chinese market. Moreover, in January 2019, Ascensia Diabetes Care, a Swiss-based diagnostics company started its operations in China in collaboration with China-based Zhejiang POCTech. The new device is continuous blood glucose monitoring and incorporates modules for digital diabetes management. Furthermore, in October 2018, Cancer Genetics, Inc., signed a distribution agreement with Genecast Biotechnology to market, distribute, and sell the Tissue of Origin (TOO) Test in China. Due to the rising prevalence of diseases and increasing government initiatives in China, the POC diagnostics market is anticipated to grow with a rapid pace during the forecast period.

In case of COVID-19, APAC is highly affected specially India. Many measures have been implemented to contain the spread of COVID-19, which have resulted in significant operational disruption for many companies including in the healthcare industry. Staff quarantine, supply-chain failures, and reductions in demand have generated serious complications for companies. Rising prevalence and incidence of COVID-19 support the growth of the market in near future forecast period. Increasing launch of PCR tests for detection COVID-19 support the growth of the market. In April 2021, Fujita Health University in Toyoake has started using a fully automated coronavirus testing system from Kawasaki Heavy Industries Ltd. The machine conducts polymerase chain reaction (PCR) test to reducing the risk of infection for technicians. Therefore, the outbreak of the COVID-19 pandemic is estimated to affect high impact on molecular biology enzymes, kits & reagents industry. Moreover, in June 2020, J Mitra & Co Pvt Ltd. an India-based company introduced its state-of-the-art COVID-19 detection kit in Indian market. Further, in May 2021, Mylab Discovery solutions, India-based company introduced home testing kits for Covid-19. The kit incorporates reverse transcription polymerase chain reaction (RT-PCR) technology. Besides, in April 2021, Celltrion, a South Korea based company announced approval and launch of its DiaTrust rapid antigen test for diagnosis of COVID-19. The kit has capacity to deliver results within 15 minutes. Also, in April 2020, India-based company Bione announced launch of India’s first home screening kit for diagnosis of COVID-19. Such product launches and approval to boost market growth during the pandemic in APAC. 


Get more information on this report

Asia Pacific Point of Care Diagnostics Strategic Insights

Strategic insights for the Asia Pacific Point of Care Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/asia-pacific-point-of-care-diagnostics-market-strategic-framework.webp
Get more information on this report

Asia Pacific Point of Care Diagnostics Report Scope

Report Attribute Details
Market size in 2021 US$ 6,548.48 Million
Market Size by 2028 US$ 15,641.78 Million
Global CAGR (2021 - 2028) 13.2%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Product
  • Glucose Monitoring Products
  • Infectious Disease Testing Products
  • Cardiometabolic Testing Products
  • Pregnancy and Fertility Testing Products
  • Coagulation Testing Products
  • Tumor/Cancer Marker Testing Products
  • Cholesterol Testing Products
  • Urinalysis Testing Products
  • Hematology Testing Products
  • Other POC Products
By Prescription Mode
  • Prescription-Based Testing
  • OTC Testing
By End User
  • Professional Diagnostic Centers
  • Home Care
  • Research Laboratories
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • Abbott
  • BD
  • bioMerieux SA
  • BIO-RAD LABORATORIES INC.
  • Danaher
  • F. HOFFMANN-LA ROCHE LTD.
  • Johnson and Johnson Services, Inc.
  • Nova Biomedical
  • Polymer Technology Systems, Inc. (PTS)
  • Siemens AG
  • Get more information on this report

    Asia Pacific Point of Care Diagnostics Regional Insights

    The geographic scope of the Asia Pacific Point of Care Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/asia-pacific-point-of-care-diagnostics-market-geography.webp
    Get more information on this report


    Market Overview and Dynamics

    The APAC point of care diagnostics market is expected to grow from US$ 6,548.48 million in 2021 to US$ 15,641.78 million by 2028; it is estimated to grow at a CAGR of 13.2% from 2021 to 2028. Point-of-care testing (POCT) plays a critical role in diagnosis, treatment, and prevention of infectious diseases. POC testing can be used to detect several major pathogens, including malarial parasites, human immunodeficiency virus (HIV), human papillomavirus (HPV), dengue, Ebola, and Zika viruses; and Mycobacterium tuberculosis (TB bacteria). The increasing incidence of infectious diseases such as HIV is the major public health issue. Moreover, healthcare-associated infections (HAIs) such as central line-associated bloodstream infections and catheter-associated urinary tract infections might affect the patients in hospitals and other healthcare facilities. Such increase in prevalence of infectious diseases is expected to create a demand for point of care test kits across the APAC region.

    Key Market Segments

    In terms of product, the glucose monitoring products segment accounted for the largest share of the APAC point of care diagnostics market in 2020. In terms of prescription mode, the prescription-based testing segment held a larger market share of the APAC point of care diagnostics market in 2020. Further, the professional diagnostic centers segment held a larger share of the APAC point of care diagnostics market based on end user in 2020.

    Major Sources and Companies Listed

    A few major primary and secondary sources referred to for preparing this report on the APAC point of care diagnostics market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; BD; bioMerieux SA; BIO-RAD LABORATORIES INC.; Danaher; F. HOFFMANN-LA ROCHE LTD.; Johnson and Johnson Services, Inc.; Nova Biomedical; Polymer Technology Systems, Inc. (PTS); and Siemens AG.  

    Reasons to buy report

    • To understand the APAC point of care diagnostics market landscape and identify market segments that are most likely to guarantee a strong return
    • Stay ahead of the race by comprehending the ever-changing competitive landscape for APAC point of care diagnostics market
    • Efficiently plan M&A and partnership deals in APAC point of care diagnostics market by identifying market segments with the most promising probable sales
    • Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form APAC point of care diagnostics market
    • Obtain market revenue forecast for market by various segments from 2021-2028 in APAC region.

    APAC Point of Care Diagnostics Market Segmentation

    APAC Point of Care Diagnostics Market - By Product

    • Glucose Monitoring Products
    • Infectious Disease Testing Products
      • HIV Testing
      • Influenza Testing
      • Sexually Transmitted Disease (STD) Testing
      • Hepatitis C Testing
      • Healthcare-Associated Infection (HAI) Testing
      • Tropical Disease Testing
      • Respiratory Infection Testing
      • Other Infectious Disease Testing
    • Cardiometabolic Testing Products
    • Pregnancy and Fertility Testing Products
    • Coagulation Testing Products
    • Tumor/Cancer Marker Testing Products
    • Cholesterol Testing Products
    • Urinalysis Testing Products
    • Hematology Testing Products
    • Other POC Products

    APAC Point of Care Diagnostics Market -

    By Prescription Mode

    • Prescription-Based Testing
    • OTC Testing

    APAC Point of Care Diagnostics Market -

    By End User

    • Professional Diagnostic Centers
      • Hospitals
      • Clinical Laboratories
      • Outpatient Healthcare
      • Ambulatory Care Settings
    • Home Care
    • Research Laboratories
    • Others  

    APAC Point of Care Diagnostics Market - By Country 

    • China
    • Japan 
    • India
    • South Korea 
    • Australia 
    • Rest of APAC

    APAC Point of Care Diagnostics Market - Company Profiles

    • Abbott    
    • BD
    • bioMerieux SA
    • BIO-RAD LABORATORIES INC.
    • Danaher
    • F. HOFFMANN-LA ROCHE LTD. 
    • Johnson and Johnson Services, Inc.
    • Nova Biomedical
    • Polymer Technology Systems, Inc. (PTS)
    • Siemens AG    

    The List of Companies - Asia Pacific Point of Care Diagnostics Market

    1. Abbott
    2. BD
    3. bioMerieux SA
    4. BIO-RAD LABORATORIES INC.
    5. Danaher
    6. F. HOFFMANN-LA ROCHE LTD.
    7. Johnson and Johnson Services, Inc. 
    8. Nova Biomedical
    9. Polymer Technology Systems, Inc. (PTS)
    10. Siemens AG
    Frequently Asked Questions
    How big is the Asia Pacific Point of Care Diagnostics Market?

    The Asia Pacific Point of Care Diagnostics Market is valued at US$ 6,548.48 Million in 2021, it is projected to reach US$ 15,641.78 Million by 2028.

    What is the CAGR for Asia Pacific Point of Care Diagnostics Market by (2021 - 2028)?

    As per our report Asia Pacific Point of Care Diagnostics Market, the market size is valued at US$ 6,548.48 Million in 2021, projecting it to reach US$ 15,641.78 Million by 2028. This translates to a CAGR of approximately 13.2% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Point of Care Diagnostics Market report typically cover these key segments-

    • Product (Glucose Monitoring Products, Infectious Disease Testing Products, Cardiometabolic Testing Products, Pregnancy and Fertility Testing Products, Coagulation Testing Products, Tumor/Cancer Marker Testing Products, Cholesterol Testing Products, Urinalysis Testing Products, Hematology Testing Products, Other POC Products)
    • Prescription Mode (Prescription-Based Testing, OTC Testing)
    • End User (Professional Diagnostic Centers, Home Care, Research Laboratories)

    What is the historic period, base year, and forecast period taken for Asia Pacific Point of Care Diagnostics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Point of Care Diagnostics Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Asia Pacific Point of Care Diagnostics Market?

    The Asia Pacific Point of Care Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Abbott
  • BD
  • bioMerieux SA
  • BIO-RAD LABORATORIES INC.
  • Danaher
  • F. HOFFMANN-LA ROCHE LTD.
  • Johnson and Johnson Services, Inc.
  • Nova Biomedical
  • Polymer Technology Systems, Inc. (PTS)
  • Siemens AG
  • Who should buy this report?

    The Asia Pacific Point of Care Diagnostics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Point of Care Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now